<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856670</url>
  </required_header>
  <id_info>
    <org_study_id>UptownEye1</org_study_id>
    <nct_id>NCT04856670</nct_id>
  </id_info>
  <brief_title>Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS</brief_title>
  <official_title>Assessing the Impact of Diabetes Mellitus on Anterior Chamber Cytokine Production and Postoperative Macular Edema in Patients Undergoing Femtosecond Laser-assisted Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uptown Eye Specialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uptown Eye Specialists</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of diabetes mellitus (DM) on anterior&#xD;
      chamber cytokine production and postoperative macular edema in patients undergoing&#xD;
      femtosecond laser-assisted cataract surgery (FLACS). Patients with DM routinely undergo&#xD;
      FLACS, yet the majority of studies evaluating intraocular inflammation following femtosecond&#xD;
      laser treatment have excluded this patient population. Importantly, DM alters the&#xD;
      inflammatory status of the eye, which may influence the production of inflammatory mediators&#xD;
      following femtosecond laser treatment and the development of postoperative macular edema. The&#xD;
      results from this study will provide insight into the risks and benefits of FLACS in patients&#xD;
      with DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As discussed above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 25, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous humor concentrations of inflammatory mediators at the onset of manual cataract surgery and following femtosecond laser treatment</measure>
    <time_frame>1 day</time_frame>
    <description>Cytokine concentration at time of cataract surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of postoperative macular edema in control and diabetic participants</measure>
    <time_frame>Post op day 1, week 1, month 1 and month 3</time_frame>
    <description>Macular edema post operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in central retinal thickness</measure>
    <time_frame>Post op day 1, week 1, month 1 and month 3</time_frame>
    <description>Central retinal thickness postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in macular volume</measure>
    <time_frame>Post op day 1, week 1, month 1 and month 3</time_frame>
    <description>macular volume postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular changes and development of cystic macular lesions</measure>
    <time_frame>Post op day 1, week 1, month 1 and month 3</time_frame>
    <description>Slit lamp exam of microvascular changes and development of cystic macular lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>Post op day 1, week 1, month 1 and month 3</time_frame>
    <description>Change in visual acuity overtime</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and severity of postoperative flare</measure>
    <time_frame>Post op day 1, week 1, month 1 and month 3</time_frame>
    <description>Slit lamp exam for prevalence and severity of postoperative flare</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cystoid Macular Edema</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Control patients undergoing manual cataract surgery</arm_group_label>
    <description>As above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients undergoing FLACS</arm_group_label>
    <description>Femtosecond laser assisted cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic patients undergoing manual cataract surgery</arm_group_label>
    <description>As Above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic patients undergoing FLACS</arm_group_label>
    <description>As Above</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract surgery- Manual or femtosecond laser assisted</description>
    <arm_group_label>Control patients undergoing FLACS</arm_group_label>
    <arm_group_label>Control patients undergoing manual cataract surgery</arm_group_label>
    <arm_group_label>Diabetic patients undergoing manual cataract surgery</arm_group_label>
    <arm_group_label>diabetic patients undergoing FLACS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolling for Cataract surgery at Uptown Eye Specialists&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who are scheduled for manual cataract surgery or FLACS who have provided&#xD;
             informed consent, in accordance with application regulations and guidelines.&#xD;
&#xD;
          -  Only one eye from each participant will be included in the study (the first one to be&#xD;
             operated on).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intravitreal anti-VEGF injection &lt; 3 months prior to cataract surgery&#xD;
&#xD;
          -  Laser photocoagulation &lt; 3 months prior to cataract surgery&#xD;
&#xD;
          -  Complications during manual cataract surgery or FLACS&#xD;
&#xD;
          -  Current or previous ocular or systemic inflammation&#xD;
&#xD;
          -  History of rheumatic or immune disease&#xD;
&#xD;
          -  Poor pharmacologic mydriasis&#xD;
&#xD;
          -  Corneal opacities&#xD;
&#xD;
          -  Pseudoexfoliation syndrome&#xD;
&#xD;
          -  Previous ocular surgery or trauma&#xD;
&#xD;
          -  Use of topical or systemic steroids &lt; 6 months prior to surgery&#xD;
&#xD;
          -  Prostaglandin analog eyedrop therapy&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Age-related macular degeneration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sydney@emdi.ca Somani, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uptown Eye Specialists</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohel Somani, MD, FRCSC</last_name>
    <phone>416.292.0330</phone>
    <email>sydney@emdi.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uptown Eye Speicialists</name>
      <address>
        <city>Brampton</city>
        <state>Otario</state>
        <zip>L6Y0P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Wu H, Hwang DK, Song X, Tao Y. Association between Aqueous Cytokines and Diabetic Retinopathy Stage. J Ophthalmol. 2017;2017:9402198. doi: 10.1155/2017/9402198. Epub 2017 Jun 7.</citation>
    <PMID>28680705</PMID>
  </reference>
  <reference>
    <citation>Dong N, Xu B, Wang B, Chu L, Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. Biomed Res Int. 2015;2015:126984. doi: 10.1155/2015/126984. Epub 2015 Feb 25.</citation>
    <PMID>25811020</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Jacob S. Current and effective advantages of femto phacoemulsification. Curr Opin Ophthalmol. 2017 Jan;28(1):49-57. Review.</citation>
    <PMID>27801688</PMID>
  </reference>
  <reference>
    <citation>Favuzza E, Becatti M, Gori AM, Mencucci R. Cytokines, chemokines, and flare in the anterior chamber after femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2019 Jul;45(7):910-914. doi: 10.1016/j.jcrs.2019.01.040.</citation>
    <PMID>31262481</PMID>
  </reference>
  <reference>
    <citation>Liu YC, Setiawan M, Ang M, Yam GHF, Mehta JS. Changes in aqueous oxidative stress, prostaglandins, and cytokines: Comparisons of low-energy femtosecond laser-assisted cataract surgery versus conventional phacoemulsification. J Cataract Refract Surg. 2019 Feb;45(2):196-203. doi: 10.1016/j.jcrs.2018.09.022. Epub 2018 Dec 6.</citation>
    <PMID>30528516</PMID>
  </reference>
  <reference>
    <citation>Wang L, Zhang Z, Koch DD, Jia Y, Cao W, Zhang S. Anterior chamber interleukin 1Î², interleukin 6 and prostaglandin E2 in patients undergoing femtosecond laser-assisted cataract surgery. Br J Ophthalmol. 2016 Apr;100(4):579-82. doi: 10.1136/bjophthalmol-2015-307586. Epub 2015 Dec 11.</citation>
    <PMID>26659713</PMID>
  </reference>
  <reference>
    <citation>Chen H, Lin H, Zheng D, Liu Y, Chen W, Liu Y. Expression of Cytokines, Chmokines and Growth Factors in Patients Undergoing Cataract Surgery with Femtosecond Laser Pretreatment. PLoS One. 2015 Sep 2;10(9):e0137227. doi: 10.1371/journal.pone.0137227. eCollection 2015.</citation>
    <PMID>26331724</PMID>
  </reference>
  <reference>
    <citation>Chen H, Zhang X, Liao N, Wen F. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy. BMC Ophthalmol. 2017 Oct 2;17(1):176. doi: 10.1186/s12886-017-0572-6.</citation>
    <PMID>28969616</PMID>
  </reference>
  <reference>
    <citation>Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC; United Kingdom Pseudophakic Macular Edema Study Group. Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. Ophthalmology. 2016 Feb;123(2):316-323. doi: 10.1016/j.ophtha.2015.10.001. Epub 2015 Dec 8.</citation>
    <PMID>26681390</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

